Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
D000433:1-Propanol / Q000627:therapeutic use*; D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D001590:Benztropine / Q000627:therapeutic use; D001712:Biperiden / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000517:prevention & control*; D010276:Parasympatholytics / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011352:Procyclidine / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D004338:Drug Combinations; D010276:Parasympatholytics; D010880:Piperidines; D011759:Pyrrolidines; D014149:Tranquilizing Agents; D014326:Tropanes; D001712:Biperiden; D001590:Benztropine; D014282:Trihexyphenidyl; D000433:1-Propanol; D011352:Procyclidine